Evidence map›Paper›PMID 31877572›Full record

ArticleBritish journal of pharmacology2020

Different receptor mechanisms underlying phytocannabinoid- versus synthetic cannabinoid-induced tetrad effects: Opposite roles of CB

Xiao-Fei Wang, Ewa Galaj, Guo-Hua Bi, Cindy Zhang, Yi He, Jia Zhan, Michael H Bauman, Eliot L Gardner, Zheng-Xiong Xi

Open access · bronzeAbstract read
In one paragraph

Article in British journal of pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 2 pooled it
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 2 syntheses or guidelines pooled it, 51 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Hepatic circadian and differentiation factors control liver susceptibility for fatty liver disease and tumorigenesis.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2022
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Xiao-Fei WangMolecular Targets and Medications Discovery Branch, National Institute on Drug Abuse, Intramural Research Program, Baltimore, Maryland.
Ewa GalajMolecular Targets and Medications Discovery Branch, National Institute on Drug Abuse, Intramural Research Program, Baltimore, Maryland.
Guo-Hua BiMolecular Targets and Medications Discovery Branch, National Institute on Drug Abuse, Intramural Research Program, Baltimore, Maryland.
Cindy ZhangMolecular Targets and Medications Discovery Branch, National Institute on Drug Abuse, Intramural Research Program, Baltimore, Maryland.
Yi HeMolecular Targets and Medications Discovery Branch, National Institute on Drug Abuse, Intramural Research Program, Baltimore, Maryland.
Jia ZhanMolecular Targets and Medications Discovery Branch, National Institute on Drug Abuse, Intramural Research Program, Baltimore, Maryland.
Michael H BaumanDesigner Drug Research Unit, National Institute on Drug Abuse, Intramural Research Program, Baltimore, Maryland.
Eliot L GardnerMolecular Targets and Medications Discovery Branch, National Institute on Drug Abuse, Intramural Research Program, Baltimore, Maryland.ORCID 0000-0003-1541-3249
Zheng-Xiong XiMolecular Targets and Medications Discovery Branch, National Institute on Drug Abuse, Intramural Research Program, Baltimore, Maryland.ORCID 0000-0001-6482-8104
National Institute on Drug Abuse · US

Funding

Endocannabinoid brain mechanisms and addictionZIADA000513 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI GARDNER, ELIOT · 2009 to 2020
$6.0M
Cannabinoid CB1 and CB2 receptors and drug abuseZIGDA000633 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI XI, ZHENG-XIONG · 2020 to 2022
$3.6M
Central CB2 Cannabinoid ReceptorsZIADA000620 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI NEWMAN, AMY HAUCK · 2017 to 2019
$860k
NIDA NIH HHS DA000620-02
6 · The paper itself

Abstract

background and purposeCannabis or cannabinoids produce characteristic tetrad effects-analgesia, hypothermia, catalepsy and suppressed locomotion, which are believed to be mediated by the activation of cannabinoid CB EXPERIMENTAL APPROACH: We compared Δ KEY

resultsSystemic administration of Δ CONCLUSIONS AND IMPLICATIONS: These findings suggest that in addition to CB

Indexed as

CannabinoidsCannabisAnimalsDronabinolMiceMice, KnockoutReceptor, Cannabinoid, CB1Receptor, Cannabinoid, CB2Receptors, CannabinoidCannabinoidsDronabinolGPR55 protein, mouseReceptor, Cannabinoid, CB1Receptor, Cannabinoid, CB2Receptors, Cannabinoid

Identifiers

PMID31877572
PMCPMC7070166
OpenAlexW2998342092

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.